Gosset Ownership
Private
Employees
~1
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Notitia Biotechnologies General Information
Notitia Biotechnologies has completed early phases of clinical trials for its lead candidate, NBT-NM108, which promotes the Foundation Guild bacteria in the gut microbiome. The company has received FDA approval for a Phase 2a trial in diabetic and prediabetic patients.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Monmouth Junction, New Jersey
United States
United States
Drug Pipeline
No pipeline data available
Key Partnerships
Notitia Biotechnologies Funding
No funding data available
To view Notitia Biotechnologies's complete valuation and funding history, request access »